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Objective: To classify a cohort of depressed adolescents recruited to the UK IMPACT trial, according to trajectories of
symptom change. We examined for predictors and compared the data-driven categories of patients with a priori
operational definitions of treatment response. Method: Secondary data analysis using growth mixture modelling
(GMM). Missing data were imputed. Trajectories of self-reported depressive symptoms were plotted using scores
taken at six nominal time points over 86 weeks from randomisation in all 465 patients. Results: A piecewise GMM
categorised patients into two classes with initially similar and subsequently distinct trajectories. Both groups had a
significant decline in depressive symptoms over the first 18 weeks. Eighty-four per cent (84.1%, n = 391) of patients
were classed as ‘continued-improvers’ with symptoms reducing over the duration of the study. A further class of
15.9% (n = 74) of patients were termed ‘halted-improvers’ with higher baseline depression scores, faster early
recovery but no further improvement after 18 weeks. Presence of baseline comorbidity somewhat increased
membership to the halted-improvers class (OR = 1.40, CI: 1.00–1.96). By end of study, compared with classes, a
clinical remission cut-off score (≤27) and a symptom reduction score (≥50%) indexing treatment response
misclassified 15% and 31% of cases, respectively. Conclusions: A fast reduction in depressive symptoms in the
first few weeks of treatment may not indicate a good prognosis. Halted improvement is only seen after 18 weeks of
treatment. Longitudinal modelling may improve the precision of revealing differential responses to treatment.
Improvement in depressive symptoms may be somewhat better in the year after treatment than previously
considered. Keywords: Depression; therapy; longitudinal studies; outcome.
Background
Adolescence denotes the highest incidence risk rate
period for the emergenceofmajor depression (MD) over
the lifecourse (Avenevoli, Knight, Kessler, & Merikan-
gas, 2008). The effectiveness of current treatment
strategies, both psychological and SSRI medication
alone or in combination (NICE, 2015), have moderate
effect sizes of between 0.3 and 0.6 (March et al., 2004;
Weisz etal., 2017).At least20%ofadolescentswithMD
show no treatment response (Goodyer et al., 2008) but
the reasons for this are unclear. Currently, there are
large variations in the definition of response between
trials (Berlim & Turecki, 2007). Such discrepancies
lower comparability between studies and impact the
proportions of patients considered responders or non-
responders, respectively (Uher et al., 2010; Vitiello
et al., 2011). Response definitions are based on
percentage symptom reduction (treatment response)
or final scores below an a priori cut-off (clinical
remission). Thesemethods are arbitrary andmay lack
clinical meaning (Thibodeau et al., 2015; Uher et al.,
2010).Furthermore, therecanbeanoverlapofpatients
meeting criteria for nonremission (e.g. a finalHamilton
Rating Scale for Depression (HRSD) score of ≥7) and a
positive clinical response (e.g. reduction of ≥50% in
HRSD) (Fu et al., 2008).
Empirical modelling techniques, such as growth
mixture modelling (GMM), may address some of the
validity issues with a priori definitions, by categoris-
ing patients post hoc (Ram & Grimm, 2009). This
computational technique searches for naturally
occurring heterogeneity to categorise patients into
particular latent classes that follow similar trajecto-
ries and make no a priori assumptions on what
constitutes a meaningful response (Briere, Rohde,
Stice, & Morizot, 2016; Thibodeau et al., 2015; Uher
et al., 2010). GMM describes the trajectory of rela-
tively homogeneous behavioural groups and how
they differ from each other in their shape over time
(Gueorguieva, Mallinckrodt, & Krystal, 2011; Ram &
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Grimm, 2009). Homogeneity of groups also aids
investigating predictors of response types that are
likely to have small effect sizes.
Growth mixture modelling analyses of treatment
trials data in depressed adults reveal a variety of
multiple, qualitatively distinct classes, specific predic-
tors and differential therapeutic responses (Cuijpers,
van Lier, van Straten, & Donker, 2005; Gueorguieva
et al., 2011; Stulz, Thase, Klein, Manber, & Crits-
Christoph, 2010; Thibodeau et al., 2015; Uher et al.,
2010). One recent report from the Treatment of Adoles-
cent Depression Study (TADS) noted that, at 12 weeks,
therewere twogroupsthat improvedover the trial,anda
further group showing limited change (Scott, Lewis, &
Marti, 2019). A depression prevention study noted two
groups where symptoms gradually reduced over time;
one group showed no change, and the other reported
resurgent symptomcountwithin6 months of the study
end (Briere et al., 2016). Unfavourable trajectories have
been associated with older age, psychosocial function,
higher anxiety symptom levels and psychotic experi-
ences (Gueorguieva et al., 2011; Jeppesen et al., 2015;
Perlis et al., 2010; Thibodeau et al., 2015).
The duration of follow-up plays a contributory role
in determining response classes. Thibodeau et al.
(2015) found that short-term follow-up mistakenly
classified some responders as nonresponders, whilst
Briere and colleagues (Briere et al., 2016) found a
subgroup of adolescents that showed a significant
decline in symptoms up to 6 months, but relapsed
only after this point. Longer-term follow-ups past the
end of the treatment may improve the precision of
denoting true responders, sustained nonresponders
and relapsing patients.
Objectives
Our primary objective was to reveal trajectories of
depression symptoms from randomisation to the
final assessment, approximately one year following
the end of treatment. The specific aims were to: (a)
define the number and shape of longitudinal classes
of patients revealed from depression symptoms only;
and (b) compare the defined groups with standard a
priori definitions of response/remission.
Our second objective was then to test whether
selected baseline demographic and clinical charac-
teristics would predict class membership.
Methods
Study design
This study was a reanalysis of data from the Improving Mood
with Psychoanalytic and Cognitive Therapies (IMPACT) trial
(Goodyer et al., 2017a; 2017b). As there we no difference in
clinical effects between psychological treatments, these were
collapsed for the present study, to investigate whole popula-
tion. Self-reported depressive symptoms were measured at six
nominal time points: baseline, 6, 12, 36, 52 and 86 weeks
postrandomisation. The last two time points were post treat-
ment which was completed by 36 weeks in >95% of the cohort.
Participants
Adolescents aged between 11 and 17 years, with major
depression (DSM-IV American Psychiatric Association, 2000),
were enrolled from 15 UK National Health Service (NHS)
clinics, 5 each in North London, North West England and East
Anglia. Patients with a lifetime history of mania were excluded.
Full details on patient inclusion and exclusion criteria can be
found in the study protocol (Goodyer et al., 2011). Four
hundred and sixty five patients who were included in the trial
had data available for the current analysis (Goodyer et al.,
2017a; 2017b).
Variables
Symptom trajectory class membership was defined using the
self-reported Mood and Feelings Questionnaire (MFQ) score
across all time points. This is a 33-item Questionnaire
(Burleson Daviss et al., 2006) of depressive symptomatology
covering the past 2 weeks measured on a 3-point scale (almost
never, sometimes, often/almost always). Higher sum scores
(range of 0–66) indicated more depressive symptoms and were
positively correlated with greater psychosocial impairment
(Goodyer et al., 2017a; 2017b).
Baseline variables investigated for their potential predic-
tive value for trajectory class membership were as follows:
sum scores from self-report measures for anxiety (the
Revised Children’s Manifest Anxiety Scale, RCMAS, Reynolds
& Richmond, 1978), obsessionality (the short Leyton Obses-
sional Inventory for adolescents (LOI), (Bamber, Tamplin,
Park, Kyte, & Goodyer, 2002) and psychosocial impairment
(the Health of the Nation Outcome Scales for Children and
Adolescents, HoNOSCA, Gowers et al., 1999). Lifetime sui-
cide attempts were defined as binary variables (yes, no) from
data derived from the Columbia Suicide Severity Rating Scale
(Posner et al., 2011). Lifetime nonsuicidal self-injury was
measured using the self-report Risk and Self Harm Inventory
for adolescents (Vrouva, Fonagy, Fearon, & Roussow, 2010).
The Kiddie-Schedule for Affective Disorder and Schizophrenia
(K-SADS, Kaufman et al., 1997) interview assessed psychi-
atric symptoms and diagnoses. Comorbidity was defined on
an ordinal scale, as the number of concurrent diagnoses.
Psychotic symptoms were counted from an ordinal scale
(absent, present: subthreshold, or present: threshold)
obtained from either of the two K-SADS screening questions
for psychosis.
Statistical methods
Imputation. Multiple imputation was used in order to
maximise sample size and reduce selection bias. Due to a
wealth of auxiliary variables predicting missingness, data were
presumed to be missing at random. Additional nonmissing
variables were also included to improve model prediction. Full
details of imputation rationale and statistical procedure are
given in Appendix S1.
Growth mixture models. There was substantial varia-
tion in the timing of each assessment and to model symptom
change accurately, the mean time of each actual assessment
(weeks) was taken as the focal point for GMMs. This corre-
sponded to baseline, 12, 18, 43, 60 and 95 weeks postran-
domisation. Variation in time of assessment was further
included as a covariate in all growth models.
We tested GMMs using the Mplus program version 8.0
(Muthen & Muthen, 2017). Four growth trends were consid-
ered: a linear and quadratic growth trend and two linear-
piecewise growth trends. We investigated piecewise growth
trends because we hypothesised that different rates of
© 2019 The Authors. Journal of Child Psychology and Psychiatry published by John Wiley & Sons Ltd on behalf of Association for
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improvement might occur during treatment versus follow-up
stages of the trial. Due to the average length of treatment
falling between the means of two assessment time points, we
considered two possible transition points in the models: the
first was placed at the third assessment (18 weeks on average
from baseline) and the second at the fourth assessment
(43 weeks from baseline).
Classes were incrementally added to the single class model
to determine the best fit. All models allowed for within-class
variation, whereby patient’s symptom scores vary around the
mean of the group. However, upon testing, there was no
evidence of significant variation between classes, (See
Appendix S1 and Table 1), meaning that the variation around
each group mean was not significantly different for the
respective classes. Consequently, between-class variation
was held equal for all growth factors. Only solutions that
were replicated with different starting values were accepted.
We considered models with 1–5 trajectory classes, and
retained the most parsimonious model. Full details of statis-
tical rules for determining parsimony are given in
Appendix S1.
Baseline clinical characteristics and predictors of
class membership. Univariate analyses were conducted
(chi-square, or t-tests) to determine whether there were signif-
icant differences between classes on baseline demographic and
clinical characteristics. Mann–Whitney–Wilcoxon tests were
performed where data were non-normal. Multinomial logistic
regression was then used to determine which variables
predicted class membership. R-squared statistic indicated
how much variance the regression model explained. Odds
Ratios are reported for all predictors.
Agreement between categorical definitions and
GMM model result. Cohen’s Kappa coefficient (Cohen,
1960) was used to test the agreement between trajectory
classes and the definitions of: (a) treatment response/nonre-
sponse (50% reduction/or not in MFQ score by end of study) or
(b) clinical remission/nonremission (MFQ score at 12 months
below or above 27) (Kent, Vostanis, & Feehan, 1997).
Results
Participants
All 465 participants who entered the trial were
available for the longitudinal analysis. Across all
assessments, 65% or more of the sample (304/465)
had full data on all MFQ items.
Outcome data
Fit information for all piecewise class models tested
is provided in Table 1. A two-class, piecewise model
that separately modelled the change in depressive
symptoms, linearly, over the first 18 weeks of treat-
ment (on average; assessments 0–2), and then the
remaining period of the trial (assessments 3–5), was
identified as the optimal model. This is illustrated in
Figure 1. BIC showed a favourable decrease of
approximately 42 with the addition of a second class
from the single class solution. Although the 3-class
solution yielded a slightly lower BIC (DBIC = 4.039),
the decrease in entropy below commonly accepted
thresholds suggests poor classification precision in
the 3-class solution (entropy = 0.844 vs. 0.734). The
Mplus code for the two-class model is provided in
Appendix S2.
The two-class piecewise GMM divided patients into
a comparatively large class of 391 (84.1%; class 1)
and a small class of 74 (15.9%; class 2). The mean
depression scores and the percentage change
between time points are shown in Table 2.
Class 2 on average showed significantly higher
baseline levels of MFQ scores than class 1 (Wald
X2(1) = 25.577, p < .001). Both classes showed a sig-
nificant decrease in MFQ score over the first 18 weeks
of the trial (6.466, p < .001, and 8.794, p < .001,
respectively). There was however, a significantly faster
rate ofMFQ reduction of class 2 comparedwith class 1
over thefirst18 weeks (WaldX2(1) = 5.446,p = .0196).
For class 2, there was no further statistical differ-
ence in rate of change over the rest of the trial (0.899,
p = .183). Conversely, class 1, on average, continued
to show a significant decline in MFQ score, albeit
slower than in the initial 18 weeks (1.639,
p = .014). This difference between the second linear
slopes of the two classes was statistically significant
(Wald X2(1) = 167.075, p < .001). By the end of the
trial, Class 1 showed on average a 60.5% improve-
ment in depressive symptoms, compared with 11.0%
in class 2. We labelled class 1 as ‘continued-im-
provers’ and class 2 as ‘halted-improvers’.
Table 1 Model fit information for piecewise GMM-CIs
Fit Statistics 1 Class 2 Classes 3 Classes 4 Classes 5 Classes
GMM-CIs
LL (No. of parameters) 10,487.996 10,454.836 10,440.533 10,431.253 10,423.269
AIC 21,015.992 20,957.672 20,937.065 20,926.506 20,918.538
BIC 21,098.832 21,057.081 21,053.042 21,059.051 21,067.651
Entropy 1 .844 .734 .718 .729
Group size (%)
C1 465 (100%) 391 (84.1%) 329 (70.7%) 191 (41.1%) 219 (47.1%)
C2 – 74 (15.9%) 77 (16.6%) 161 (34.6%) 109 (23.5%)
C3 – – 59 (12.7%) 57 (12.3%) 56 (12.0%)
C4 – – – 56 (12.0%) 54 (11.6%)
C5 – – – – 27 (5.8%)
© 2019 The Authors. Journal of Child Psychology and Psychiatry published by John Wiley & Sons Ltd on behalf of Association for
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Baseline characteristics of each class
The characteristics of patients following each trajec-
tory class are described in Table 3.
There were more females in the ‘halted’ compared
with the ‘continued’ improvers class (85% vs. 73%).
No other demographic characteristics were signifi-
cantly different between groups.
Compared with. ‘continued-improvers’, ‘halted-
improvers’ on average showed significantly higher
obsessionality (LOI) and HoNOSCA scores, more
nonsuicidal self-injury (NSSI), and greater
numbers of comorbid diagnoses at baseline.
Interestingly neither baseline levels of suicidal
attempts, psychotic symptoms nor treatment
group discriminated between the classes. There
were no significant differences between the two
classes on any baseline characteristic (Table 3).
Trajectories of classes were similar for HoNOSCA
as for MFQ, as a concurrent validation check
(Appendix S3).
Predictors of trajectory class membership
Class 1 acted as the reference class for the logistic
regression (Table 4). When controlling for variables
included in the model, only the number of comorbid
psychiatricdiagnosesatbaselinesignificantlypredicted
ahigher probability ofmembership to halted-improvers
compared with continued-improvers (Table 4). With
each increasing number of comorbid diagnoses the
oddsofapatientbelonging to the ‘halted’ comparedwith
the ‘continued-improvers’ class increased by a factor of
1.4 (X2(4) = 46.03, p < .001). The finding however only
explained 5.4% of the total variance in class member-
ship (Cox and Snell R2 = .054).
Agreement between classes and categorical
definitions of response
The agreement in classification between data-driven
classes and a priori categorical classifications are
shown in Figure 2.
Figure 1 Sample (shown in large grey/black) and estimated (shown in small black) means for the two-class piecewise growth mixture
model. Class 1 reveal a continued-improver class, n = 391 (84.1%) of the population. Class 2 reveal halted-improver class, n = 74 (15.9%)
of the population. Behind plots every individual patient’s trajectory
Table 2 Estimated and observed mean values for MFQ scores and observed mean percentage improvement in MFQ scores are given
for both latent classes
Assessment point in
average weeks from
baseline
Class 1: Continual improvement (n = 391) Class 2: Halted improvement (n = 74)
MFQ sum scores MFQ sum scores
Estimated
Weighted
estimates Observed
% observed
improvement
from baseline Estimated
Weighted
estimates Observed
% observed
improvement
from baseline
0 44.828 44.810 44.774 51.638 51.721 52.096
12 37.073 34.649 34.623 22.672 41.090 38.191 38.420 26.252
18 32.881 32.752 32.689 26.991 35.390 36.134 36.558 29.826
43 25.877 23.938 25.920 42.109 39.232 38.243 38.669 25.774
60 23.039 22.291 22.224 50.364 40.789 39.034 39.835 23.535
95 17.247 17.797 17.673 60.528 43.966 44.978 46.357 11.016
© 2019 The Authors. Journal of Child Psychology and Psychiatry published by John Wiley & Sons Ltd on behalf of Association for
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Percentage symptom reduction
There was moderate agreement between trajectory
class membership and clinical categorical outcome
when ‘treatment response’ is defined by percentage
reduction of 50% by end of study (k = .412,
p < .001). All halted-improvers were also treatment
nonresponders by this definition. However, only 269
of 391 (69%) of continued-improvers were also
treatment responders. The remaining continued-
improvers (122 of 391; 31%) were classified as
treatment nonresponders on the per cent reduction
category.
Clinical cut-off
There was stronger, albeit still moderate, agreement
between trajectory membership and clinical remis-
sion, when defined by a cut-off score of 27 on the
MFQ (k = .642, p < .001) at end of study. All halted-
improvers were also clinical nonremitters. However,
only 332 of 391 (85%) of continued-improvers were
classified as in clinical remission. The remaining
continued-improvers (59 of 391; 15%) were classified
as not clinically remitted.
Overall, if either a priori category definitions had
been used in this study a false negative classification
rate of either 15% or 31% would have been
reported.
Table 3 Characteristics of subjects following the two latent trajectories
Class 1: Continued-
improvers (n = 391)
Class 2: Halted-
improvers (n = 74) Comparison
Mean (n) SD (%) Mean (n) SD (%) X2/t/W p
Demographics
Female 285 72.8% 63 85.1% 4.955 .026
Age 15.6 1.4 15.7 1.3 0.459 .647
Region – – – – 2.035 .361
East Anglia 161 41.2% 24 32.4% – –
North London 105 26.9% 22 29.7% – –
North West England 125 32.0% 28 37.8% – –
Ethnicity (white) 325 83.1% 65 87.8% 1.024 .312
Index of multiple deprivation (IMD)a 23.4 – 27.7 – 13,446 .336
Baseline clinical characteristics
RMASb 40.7 7.3 42.3 6.7 1.863 .065
LOIc 9.6 5.1 11.8 5.6 3.124 .002
Suicidal thoughts 345 88.2% 69 93.2% 1.600 .206
Suicidal attempts 131 33.5% 28 37.8% 0.519 .471
NSSI 218 55.8% 53 71.6% 6.443 .011
HONOSCA (available for 435 patients) 18.3 6.0 19.9 6.3 2.018 .046
Comorbidityd – – – – 10.20 .006
1 121 30.9% 26 35.1% – –
2 59 15.1% 18 24.3% – –
3 5 1.3% 3 4.1% – –
4 0 0% 1 1.4% – –
Psychotic symptoms – – – – 2.024 .363
Subthreshold 87 23.6% 16 22.5% – –
Threshold 32 8.8% 10 14.1% – –
Treatment characteristics
Treatment arm – – – – 2.463 .292
BPI 127 32.5% 28 37.8% – –
CBT 127 32.5% 27 36.5% – –
STPP 137 35.0% 19 25.7% – –
Baseline SSRI prescription 87 22.3% 10 13.5% 2.877 .090
aIMD: Median reported for nonparametric tests.
bRevised Manifets Anxiety Scale- self-report.
cLeyton Obsessional Inventory- self-report.
dDue to insufficient cell size, variable was recorded as 0,1 and 2+ to meet assumptions of chi-square test.
Table 4 Baseline predictors of trajectory class membership:
clinical characteristics
Class 1: Halted-improvers
OR 95% CI
Gender 0.50 0.23–1.02
Age 1.02 0.84–1.26
RCMAS 0.98 0.94–1.03
LOI 1.06 0.99–1.12
HONOSCA 1.03 0.98–1.08
Attempts 0.98 0.53–1.79
NSSI 1.77 0.95–3.41
Psychotic symptoms 0.97 0.64–1.45
Comorbidity 1.40* 1.00–1.96*
*<.05.
© 2019 The Authors. Journal of Child Psychology and Psychiatry published by John Wiley & Sons Ltd on behalf of Association for
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Figure 2 Sample means for the three categorical approaches. (A) Trajectory classes. (B) Percentage reduction for treatment response. (C)
Clinical cut-off for remission. Behind plots every individual patient’s trajectory
© 2019 The Authors. Journal of Child Psychology and Psychiatry published by John Wiley & Sons Ltd on behalf of Association for
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Discussion
Key results and interpretation
Using a cohort of depressed adolescents recruited
into a clinical trial we computed a depression symp-
tom trajectory that revealed a piecewise function,
with two separate linear trajectories. The best fit
model was for two classes defined as a large (84.1%)
group of continued-improvers and a small (15.9%)
group of halted-improvers. We noted that both
groups improved significantly over the first 18 weeks
of the trial. The halted group showed a cessation in
improvement from thereon, and this may index a
putative relapsing group but this requires replicaton.
Although there are studies that support the exis-
tence of more than two classes, these applied con-
straints on investigated trajectory shape (Stulz et al.,
2010; Thibodeau et al., 2015) and eliminated within-
class variation from their models (Briere et al.,
2016). These methodological choices are often nec-
essary when models struggle to converge (Wickrama
et al., 2016). To assume that no individual variation
exists within classes in depressive patients, we felt
was not representative of real data. We therefore
favoured a GMM analysis at outset, which would
allow for within-class variation. Our results were
stable across different sets of random starting values
without these constraints, offering a much more
representative model of patient experience of depres-
sive symptom change.
A striking finding in the present study was the great
contrast between trajectories of the two groups across
both parts of the model. The faster decline of halted-
improvers may itself be due to the higher depression
ratings at baseline. This does not necessarily index
‘good treatment response’: indeed clinicians may need
to consider that a fast reduction in depressive symp-
toms may imply subsequent halted improvement.
Further, treatment response cannot be prognostically
assessed adequately before approximately 18 weeks.
The precise psychological treatment implications how-
ever cannot be determined as there was no placebo
control group: we do not know whether this period of
rapid improvement is due to the psychological therapy,
a nonspecific response to receiving assessment and
treatment, or regression to the mean. Nevertheless,
these findings indicate that clinical care should be
taken for those adolescents with greater levels of
comorbidity and depression severity at baseline, even
when there is an initial rapid response to treatment.
Previous studies reporting two classes describe
their trajectory groups as either rapid and gradual
responders, or responders and nonresponders
(Gueorguieva et al., 2011; Uher et al., 2010). One
recent study of adolescents reported three trajectory
classes with the two improving classes merging by
end of treatment (Scott et al., 2019). However, those
studies were limited to short trial durations of
12 weeks or less and were not able to assess
longer-term outcome. The shape of the halted-im-
provers trajectory in this clinical study resonates with
the symptomresurgence group reportedbyBriere and
colleagues in their community-sample depression
prevention study (Briere et al., 2016). Their resur-
gence group showed a similar rapid initial improve-
ment in symptoms, followed by a rapid decline in
symptoms over time. Whilst the slope value for the
second section of our trajectory in the halted-im-
provers did not reach significance with this cohort,
visual inspection suggests this trend. This trajectory
shape suggests that different underlying therapeutic
mechanisms may be activated in early and subse-
quent treatment responses. For example, the halted-
improvers may contain patients who are clinically
relapsing as well as not responding. What factors
account for the 18-week assessment as the optimal
break point of responding is not clear. Longer-term
follow-up is essential in future studies to disentangle
group trajectory patterns more accurately and to
reveal the most valid prognostic markers for treat-
ment response both early and later in follow-up.
Mediationanalyseswill be required to examine factors
and mechanisms involved in early relapse and to
separate these from nonresponse.
Despite baseline univariate differences, only
comorbidities at baseline was retained as a signifi-
cant independent predictor with a small odds ratio
and low predictive power. We conclude that baseline
demographic and clinical observations are insuffi-
cient to fully predict depression symptom change
over time. We also note that self-reported illness
episode duration was not a moderator of treatment
response in the primary results nor here (Goodyer
et al., 2008). Although data were not available in this
study, we conjecture that, consistent with a number
of other randomised controlled trials, a history of
childhood maltreatment could have been a modera-
tor of trajectory group membership, with a positive
history increasing the liability for being a halted-
improver (Goodyer & Wilkinson, 2019). Further we
note that, although patients with a history of mania
were excluded from the study, such symptoms may
have emerged over the treatment phase. Indeed, we
recognise that a next step from this report is to
consider what factors over the course of treatment
and then follow-up phases may influence member-
ship of the continued or halted-improvers groups.
We plan to conduct mediation analyses to examine
the effects of treatment dose, symptom and psy-
chosocial changes and SSRI prescribing over the
treatment phase and their possible impact on mem-
bership of continued or halted outcome groups.
Finally, the findings showed only moderate agree-
ment between empirical and a priori definitions of
symptom change indexing clinical response or
remission. This is similar to results of previous
studies (Gueorguieva et al., 2011; Uher et al.,
2010). The findings here have provided a clear cut
© 2019 The Authors. Journal of Child Psychology and Psychiatry published by John Wiley & Sons Ltd on behalf of Association for
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consistent group of halted-improvers by end of
study, potentially predicted by higher depression
scores and levels of comorbidity at entry combined
with halted improvement by 18 weeks. This suggests
caution with the use of cut-off or percentage change
measures as indices of achieving clinical remission,
as it is possible that a significant percentage of
potentially responding patients might be misclassi-
fied too quickly as nonresponders to treatment. Until
more is known about subclasses of depression,
researchers must take care in their choice of out-
come measure and in particular to try to minimise a
false negative result.
Limitations
We cannot use these findings to generalise to
population-based trials where recruitment takes
place from schools, community settings or patients
with distinct cultural differences to those in this UK
NHS study. We do not know if the addition of parent
or teacher reporting, as opposed to self-reported
measures would have aided these research findings.
GMM are large-sample statistical techniques, and
whilst a sample of 465 is sufficient, a sample of 600
or more may have seen the emergence of a more
stable 3-class model. The lack of nonsymptom
driven 86-week outcome validators, such as inter-
personal function, or data on history of childhood
maltreatment, are other limitations of this paper.
However, investigation of HONOSCA, a measure of
functioning as well as psychiatric symptomatology,
showed similar trends to MFQ (Appendix S3), which
provides preliminary external validity for our find-
ings. In future, GMM trajectories in clinical popu-
lations with multiple symptom profile could utilise
nondepressive symptoms in their longitudinal
analyses.
Supporting information
Additional supporting information may be found online
in the Supporting Information section at the end of the
article:
Appendix S1. Statistical methods.
Appendix S2. Mplus code for the two-class, piecewise
model.
Appendix S3. Validation with HONOSCA.
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Key points
 At least 20% of moderate to severely depressed adolescents show no response to current treatments.
 Modelling of depressive symptom trajectories of change suggested that 84.1% of depressed adolescents
could be considered as ‘continued responders’, whilst 15.9% could be classed as ‘halted responders’, that is
showing significant decrease in depression severity over the first 18 weeks, which then halted over the
subsequent year.
 By the end of study, ‘continued responders’ showed on average a 60.5% improvement in depressive
symptoms, compared with 11.0% amongst the halted-improvers.
 A fast reduction in depressive symptoms may not indicate a good prognosis.
 Clinical progress continues in the year after treatment and overall may be better than previously considered
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